Concomitant medication of psychoses in a lifetime perspective
(2011) In Human Psychopharmacology: Clinical and Experimental 26(4-5). p.322-331- Abstract
- Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs... (More)
- Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics. Conclusions Most psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright (C) 2011 John Wiley & Sons, Ltd. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2162024
- author
- Vares, Maria ; Saetre, Peter ; Stralin, Pontus ; Levander, Sten LU ; Lindstrom, Eva and Jonsson, Erik G.
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antipsychotic drugs, concomitant medication, schizophrenia, retrospective, poly-pharmacy, lifetime
- in
- Human Psychopharmacology: Clinical and Experimental
- volume
- 26
- issue
- 4-5
- pages
- 322 - 331
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000293964700007
- scopus:79960847925
- pmid:21695733
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.1209
- language
- English
- LU publication?
- yes
- id
- cd87a4d6-5b3a-4943-b236-c92f035498b1 (old id 2162024)
- date added to LUP
- 2016-04-01 10:43:31
- date last changed
- 2022-01-26 01:52:54
@article{cd87a4d6-5b3a-4943-b236-c92f035498b1,
abstract = {{Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics. Conclusions Most psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright (C) 2011 John Wiley & Sons, Ltd.}},
author = {{Vares, Maria and Saetre, Peter and Stralin, Pontus and Levander, Sten and Lindstrom, Eva and Jonsson, Erik G.}},
issn = {{0885-6222}},
keywords = {{antipsychotic drugs; concomitant medication; schizophrenia; retrospective; poly-pharmacy; lifetime}},
language = {{eng}},
number = {{4-5}},
pages = {{322--331}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Human Psychopharmacology: Clinical and Experimental}},
title = {{Concomitant medication of psychoses in a lifetime perspective}},
url = {{http://dx.doi.org/10.1002/hup.1209}},
doi = {{10.1002/hup.1209}},
volume = {{26}},
year = {{2011}},
}